Researchers sought to determine the relationship among hospitalization for COPD exacerbation, AF burden, and risk for subsequent stroke.

Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

One-year clinical trial data for the next-generation, investigational, Sphere-360TM single-shot PFA catheter show impressive safety, perf ...

Abbott has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volttm PFA System ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Barclays analyst Matt Miksic raised the firm’s price target on Boston Scientific (BSX) to $125 from $118 and keeps an Overweight rating on the ...

Boston Scientific’s FARAPULSE system is showing some serious promise in zapping away persistent atrial fibrillation, ...